Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer: a Phase II Clinical Study

NCT05051722 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05051722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05051722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer: a Phase II Clinical Study
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Recruiting
Start date
August 3, 2021
Completion date
June 30, 2027
Enrollment
3,110 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

adnexal mass, atypical endometrial hyperplasia, cervical cancer, cervical dysplasia, endometrial cancer, ovarian cancer